No one ever wants to hear that their child has cancer. But if it happens, you do want to hear that you have one of the leading-edge children's cancer centers nearby–Cook Children's.
Cancer in children, teens and young adults is rare, and some types of childhood cancers are extremely rare. Finding an experienced team that has treated those cancers is literally a life-altering decision.
The oncology program at Cook Children's is one of only a handful of pediatric cancer programs in the southwest, and one of only four in Texas that are a Children's Oncology Group member institute. In addition, our team of physician-researchers is among the most respected in the country. What that means to you and your child is access to tomorrow's treatments and cures, today.
Our doctors are actively pursuing cures for cancer. Because of our participation in ongoing national research studies, we are able to offer many patients the opportunity to participate in studies, giving them access to the most recent medicines and advanced treatments, including genetics, nuclear medicine, stem cell transplants, and more.
Our cancer center includes stem cell transplant rooms, an inpatient and outpatient infusion center, 28 inpatient beds in private rooms, a dedicated pharmacy, Texas' first and only I-131-MIBG suite for advanced targeted treatment of neuroblastoma tumors.
While our specialty is treating and curing cancer in our patients, we also take extra care of their childhood and teen years so that they can have the support and do not pause their lives as they grow into happy, healthy adults.
The oncology program at Cook Children's is open to any child from infancy through young adulthood who is suspected of having cancer, has been diagnosed with cancer, or who wants a second opinion. Our patients range in age from newborn to early 20s, and sometimes even older if we are one of the only centers close by that treats the type of cancer they have. We see patients from our local area and those in other states in even other countries. And thanks to the support of our community and our social services team, we never turn away a child who needs care simply because they can't afford it.
The oncology team at Cook Children's treats all types of cancers and tumors in children, including:
A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2022-024 (OPEN)
Study Information Request Information
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) - ACNS1821
IRB ID: 2022-054 (OPEN)
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-006 (TEMPORARILY CLOSED TO ACCRUAL)
A Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma
Primary Investigator: Granger MD, Meaghan
IRB ID: 2021-086 (TEMPORARILY CLOSED TO ACCRUAL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
IRB ID: 2017-049 (TEMPORARILY CLOSED TO ACCRUAL)
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
IRB ID: 2021-071 (OPEN)
Request Information
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Primary Investigator: Albritton MD, Karen
IRB ID: 2022-122 (OPEN)
A Phase 3 Randomized Study of Selumetinib (IND #77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG))
Primary Investigator: Murray MD, Jeffrey
IRB ID: 2019-075 (OPEN)
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
IRB ID: 2020-072 (OPEN)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
IRB ID: 2020-022 (OPEN)
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
IRB ID: 2022-019 (OPEN)
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations - ACNS1931
IRB ID: 2021-017 (TEMPORARILY CLOSED TO ACCRUAL)
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
IRB ID: 2019-059 (OPEN)
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Primary Investigator:
IRB ID: TACL_T2020-006_Heym (TEMPORARILY CLOSED TO ACCRUAL)
A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
IRB ID: 2020-087 (TEMPORARILY CLOSED TO ACCRUAL)
A Phase II Trial Of Epigenetic Priming In Patients With Newly Diagnosed Acute Myeloid Leukemia
IRB ID: 2017-031 (OPEN)
A Randomised Phase 3 trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours
Primary Investigator: Vallance MD, Kelly
IRB ID: 2018-089 (OPEN)
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
IRB ID: 2021-083 (OPEN)
A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy
IRB ID: 2021-016 (OPEN)
A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors)
IRB ID: COG_ARST1921_Vallance (TEMPORARILY CLOSED TO ACCRUAL)
A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
IRB ID: 2019-036 (OPEN)
Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors. A COG Groupwide Observational Study.
Primary Investigator: Beam MD, Donald
IRB ID: COG_ALTE21C1_Beam (OPEN)
CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
IRB ID: 2020-066 (OPEN)
COG Study ALTE03N1: Key Adverse Events after Childhood Cancer
IRB ID: 543 (OPEN)
COG_AHOD2131_Albritton
IRB ID: 2023-056 (OPEN)
Exploration of Perceived Stress, Sleep, Fatigue, and Biomarkers in Childhood Brain Tumor Survivors
Primary Investigator: Bashore NP, Lisa M
IRB ID: 2018-010 (OPEN)
Fort Worth AYA Oncology Coalition Registry Database
IRB ID: 2019-017 (OPEN)
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
IRB ID: 2014-023 (OPEN)
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
IRB ID: 2017-048 (OPEN)
Kaposiform Hemangioendothelioma: Hematology and Oncology Survey (KHHAOS) Study
IRB ID: 2021-051 (OPEN)
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
IRB ID: 2010-109 (OPEN)
National Registry of Pediatric Cancer Patients Diagnosed with COVID-19
IRB ID: 2020-034 (OPEN)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 study of LOXO-101 (Larotrectinib) in patients with tumors harboring NTRK fusions (APEC1621A)
IRB ID: 2018-006 (OPEN)
NCI-COG Pediatric Match (Molecular Analysis For Therapy Choice) - Phase 2 Subprotocol Of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations (APEC1621K)
IRB ID: 2020-055 (OPEN)
NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Loxo-292 in Patients with Tumors Harboring Ret Gene Alterations (APEC1621N)
IRB ID: 2020-099 (OPEN)
NCI-COG Pediatric Match (Molecular Analysis For Therapy Choice) - Phase 2 Subprotocol of Tipifarnib in Patients with Tumors Harboring Hrasgenomic Alterations (APEC1621M)
IRB ID: 2020-070 (OPEN)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 study of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations (APEC1621F)
IRB ID: 2018-003 (OPEN)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol (APEC1621SC)
IRB ID: 2017-065 (OPEN)
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer (ALTE07C1)
IRB ID: 2009-013 (OPEN)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Primary Investigator: Akers DO, Lauren
IRB ID: 2018-066 (OPEN)
PEPN22P1: A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
Primary Investigator: Pacenta, Holly
IRB ID: 2022-112 (OPEN)
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
IRB ID: 2021-077 (OPEN)
Protocol Addendum J1S-MC-JV01(d) A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
IRB ID: 2020-067 (OPEN)
Randomization of Cytarabine Monotherapy versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis
Primary Investigator: Ray MD, Anish
IRB ID: 2019-067 (OPEN)
Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium Retrospective Chart Review
IRB ID: 2019-051 (OPEN)
SELCLAX
IRB ID: 2021-056 (OPEN)
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
IRB ID: St. Jude_SJiMB21_Zhao (OPEN)
Tissue Banking- Collecting and Banking Human Tissue Samples for Future Use
IRB ID: 2020-093 (OPEN)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
IRB ID: 2020-097 (OPEN)
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (Tapistry) Phase II Platform Trial
IRB ID: 2020-064 (OPEN)
Venetoclax EAP IND 152442
IRB ID: 2020-080 (OPEN)
If your child has been diagnosed, you probably have lots of questions. We can help. If you would like to schedule an appointment, refer a patient or speak to our staff, please call our offices at 682-885-4007.
